US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi Genomics & Precision Medicine ETF

35.30

-0.5420-1.51%

Post-market: 35.300.00000.00%16:10 EDT

Volume:12.26K

Turnover:433.83K

Market Cap:1.59M

PE:- -

High:35.84

Open:35.84

Low:35.04

Close:35.84

52wk High:35.84

52wk Low:23.88

Shares:45.00K

Float Shares:45.00K

Volume Ratio:6.91

T/O Rate:27.25%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Illumina Secures New Syndicated Credit Facility Agreement

Illumina - Enters Credit Agreement on August 13, 2026

Illumina Enters USD 1 Billion Five-Year Revolving Credit Facility with Bank of America-Led Lenders

Illumina - Credit Agreement Provides for $1 Bln Five-Year Revolving Credit Facility - SEC Filing

THOMSON REUTERS

Illumina - Credit Agreement Includes Option to Increase Commitments or Term Loans up to $500 Mln - SEC Filing

THOMSON REUTERS

Thermo Fisher EVP Michael D. Shafer Disposes of 25,500 Common Shares Worth $15.3 Million Under 10b5-1 Plan

Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

MT Newswires Live

Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?

Simply Wall St.

Illumina Prices $300 Million Notes Offering Due 2029

Thermo Fisher Completes Sale of Microbiology Business to Astorg for $1.08 Billion

Thermo Fisher Scientific Completes Sale of Its Microbiology Business to Astorg

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Brookdale Senior Living (BKD) and Legend Biotech (LEGN)

Vertex 1Q Net Y772.00m vs Net Y658.00m

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares

Illumina Ajukan Form 3; Chief Legal Officer Julie Ann Coletti Laporkan Kepemilikan Manfaat Awal

Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says

MT Newswires Live

Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)

Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/GNMX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GNMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","market":"US","secType":"STK","nameCN":"Corgi Genomics & Precision Medicine ETF","latestPrice":35.2952,"timestamp":1787601600000,"preClose":35.8372,"halted":0,"volume":12264,"hourTrading":{"tag":"盘后","latestPrice":35.2952,"preClose":35.2952,"latestTime":"16:10 EDT","volume":7,"amount":247.06640000000002,"timestamp":1787602204674,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.015123949415691002,"floatShares":45000,"shares":45000,"eps":0,"marketStatus":"Post-Mkt","change":-0.542,"latestTime":"08-24 16:28:53 EDT","open":35.8372,"high":35.8372,"low":35.035,"amount":433831,"amplitude":0.022385,"askPrice":52.92,"askSize":200,"bidPrice":17.64,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1302235200000,"exchange":"CBOE","adjPreClose":35.8372,"nav":35.12,"aum":1580400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.2952,"preClose":35.2952,"latestTime":"16:10 EDT","volume":7,"amount":247.06640000000002,"timestamp":1787602204674,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":6.909296,"impliedVol":0.1803,"impliedVolPercentile":0.3582},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","floatShares":45000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":6.909296,"shares":45000,"dividePrice":0,"high":35.8372,"amplitude":0.022385,"preClose":35.8372,"low":35.035,"week52Low":23.88,"pbRate":"--","week52High":35.8439,"institutionHeld":0,"latestPrice":35.2952,"eps":0,"divideRate":0,"volume":12264,"delay":0,"ttmEps":0,"open":35.8372,"prevYearClose":25.56,"prevWeekClose":35.8372,"prevMonthClose":29.7248,"prevQuarterClose":31.0879,"fiveDayClose":32.3271,"twentyDayClose":29.7525,"sixtyDayClose":26.8115},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNMX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNMX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GNMX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659160249","title":"Illumina Secures New Syndicated Credit Facility Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160249","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160249?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:58","pubTimestamp":1786654723,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Illumina ( ($ILMN) ). On August 13, 2026, Illumina, Inc. entered into a credit agreement with a syndicate of le...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/illumina-secures-new-syndicated-credit-facility-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/illumina-secures-new-syndicated-credit-facility-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ILMN","BK4548","BK4588","LU0029874061.USD","BK4585","BK4121","LU0128526141.USD","GNMX","GNOM","BK4535","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659716090","title":"Illumina - Enters Credit Agreement on August 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659716090","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659716090?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:58","pubTimestamp":1786654702,"startTime":"0","endTime":"0","summary":"BRIEF-Illumina - Enters Credit Agreement On August 13, 2026Aug 13 -Illumina IncILMN.O:ILLUMINA - ENTERS CREDIT AGREEMENT ON AUGUST 13, 2026 - SEC FILINGILLUMINA - CREDIT AGREEMENT PROVIDES FOR $1 BILLION FIVE-YEAR REVOLVING CREDIT FACILITY - SEC FILINGILLUMINA - CREDIT AGREEMENT INCLUDES OPTION TO INCREASE COMMITMENTS OR TERM LOANS UP TO $500 MILLION - SEC FILINGFurther company coverage:ILMN.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GNOM","BK4535","BK4534","BK4121","ILMN","LU0128526141.USD","LU0029874061.USD","GNMX","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167148","title":"Illumina Enters USD 1 Billion Five-Year Revolving Credit Facility with Bank of America-Led Lenders","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167148?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:29","pubTimestamp":1786652993,"startTime":"0","endTime":"0","summary":"Illumina enters USD 1 billion five-year revolving credit facility with Bank of America-led lendersIllumina entered a new senior unsecured five-year revolving credit facility of $1 billion on Aug. 13, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL4XmN3n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYF","IE00B19Z3581.USD","BK4588","LU0052756011.USD","VFH","LU0098860793.USD","XLF","LU0787776722.HKD","LU0306807586.USD","IE00BLSP4239.USD","LU1201861165.SGD","LU0149725797.USD","LU1162221912.USD","LU0130102774.USD","LU0683600562.USD","LU1280957306.USD","LU2129689514.USD","LU1267930227.SGD","UYG","LU1894683348.USD","LU0128526141.USD","FTXO","BK4548","KBWB","LU0320765489.SGD","LU2133065610.SGD","TFNS","FNCL","BK4585","BK4559","ILMN","LU0321505439.SGD","LU1718418525.SGD","LU1074936037.SGD","LU1894683264.USD","GNOM","GNMX","BAC","LU0256863902.USD","LU0310800965.SGD","IYG","LU2265009873.SGD","LU0417517546.SGD","LU0170899867.USD","IE00BFXG1179.USD","LU0053666078.USD","LU1363072403.SGD","LU0029874061.USD","LU1291159041.SGD","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659673001","title":"Illumina - Credit Agreement Provides for $1 Bln Five-Year Revolving Credit Facility - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659673001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659673001?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652505,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1N2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4121","ILMN","LU0128526141.USD","BK4548","BK4534","LU0029874061.USD","BK4535","GNMX","GNOM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167664","title":"Illumina - Credit Agreement Includes Option to Increase Commitments or Term Loans up to $500 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167664?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:21","pubTimestamp":1786652505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1N2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4588","BK4534","BK4121","GNMX","ILMN","BK4585","GNOM","BK4548","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164067","title":"Thermo Fisher EVP Michael D. Shafer Disposes of 25,500 Common Shares Worth $15.3 Million Under 10b5-1 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164067","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164067?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:02","pubTimestamp":1786651375,"startTime":"0","endTime":"0","summary":"Thermo Fisher EVP Michael D. Shafer disposes of 25,500 common shares worth $15.3 million under 10b5-1 planThermo Fisher Executive Vice President Michael D. Shafer sold 25,500 shares on Aug. 11 at USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL2cbkgB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Thermo Fisher EVP Michael D. Shafer Disposes of 25,500 Common Shares Worth $15.3 Million Under 10b5-1 Plan","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","BK4533","LU2764263039.SGD","LU0823416689.USD","IE00BKPKM429.USD","HRTS","LU0320765489.SGD","IE00BQXX3D17.EUR","LU1988902786.USD","LU2125909759.SGD","LU0096362180.USD","FMED","LU2357305700.SGD","TMO","BK4585","LU2063271972.USD","BK4588","LU0029864427.USD","LU1720051017.SGD","IE00BJT1NW94.SGD","GNMX","LU1983299246.USD","LU2764263203.CNY","LU0557290698.USD","LU1057294990.SGD","LU1633808545.USD","LU0266013472.USD","LU2125909916.SGD","BK4548","LU0708994859.HKD","LU2041044095.USD","LU2089984988.USD","LU2125909247.SGD","LU1670628061.USD","IE00B19Z8W00.USD","IE00B19Z9505.USD","LU1923622291.USD","LU2298321311.HKD","LU0310800379.SGD","LU0234572021.USD","LU0122379950.USD","LU0432979614.USD","LU1267930573.SGD","IE00BQXX3C00.GBP","LU1791710582.SGD","TMED","LU0342679015.USD","LU1803068623.USD","LU1670627923.USD","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659245165","title":"Alnylam Pharma (ALNY) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659245165","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659245165?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635358,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma today and set a price target of $318.00. According to TipRanks, Matt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alnylam-pharma-alny-receives-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4127","LU0109394709.USD","BK4548","LU0882574055.USD","PBE","ALNY","BK4139","BK4588","BK4585","LU0889565916.HKD","GNMX","LU0114720955.EUR","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","LENZ","BK4007","MRNX","FRTY","TBXU","MRNY","BK4139","LABU","MEDI","GNMX","GDOC","IDNA","BK4588","PINK","IYH","IBB","SYNB","XLVX","NVIB","PSCH","BK4585","BK4539","LFSC","BMED","RSPH","BBP","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658290503","title":"Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658290503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658290503?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:02","pubTimestamp":1786546971,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in patients with cystic fibrosis in H2, with a positive readout potentially strengthening its competitive advantage in the space, RBC analysts said.Favorable data will likely result in modest upside, while unfavorable data will likely lead to little downside, the analysts added.Meanwhile, approval by the US Food and Drug Administration for Vertex's povetacicept in immunoglobulin A nephropathy, with a PDUFA date of Nov. 30, 2026, is likely due to strong interim phase 3 results, the analysts said.They said that the drug's differentiated profile could make it the preferred choice of most doctors.With Sionna Therapeutics  failing to demonstrate significant sweat chloride improvements as an add-on to Trikafta, one of the more ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","LU0058720904.USD","GNMX","BK4139","IDNA","IE00B19Z9P08.USD","LU0079474960.USD","LU2237438978.USD","IBB","IE00B19Z3B42.SGD","LU0109394709.USD","LU0061475181.USD","SION","LU0889565916.HKD","LU0566484027.USD","LU1430594728.SGD","PBE","LU2362541513.USD","LU2324357040.USD","BK4023","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4567","VERX","VRTX","LU2362540622.SGD","LU1674673691.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","LU2417539215.USD","IE00B19Z3581.USD","BK4585","IBBQ","BBH","LU2456880835.USD","SG9999013999.USD","LU1815336091.USD","TBXU","LU1559883803.SGD","LU0417517546.SGD","LU1069344957.HKD","IE00BFTCPJ56.SGD","LU2362541273.HKD","BIB","IE00B2B36J28.USD","BK4532","LU1093756325.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908275","title":"Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908275","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908275?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:26","pubTimestamp":1786537582,"startTime":"0","endTime":"0","summary":"In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, a shift from a net loss a year earlier, and for the first half of 2026 revenue reached US$2,458.12 million with net income of US$370.49 million. \nOn the same day, the company trimmed its full-year 2026 guidance for total net product revenues while raising expectations for collaboration and royalty income, highlighting a changing balance between its own drug...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylams-mixed-2026-guidance-reset-altering-the-investmen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/is-alnylams-mixed-2026-guidance-reset-altering-the-investmen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0882574055.USD","PBE","BK4588","BK4585","GNMX","LU0320765992.SGD","BK4139","LU0889565916.HKD","LU0109394709.USD","BK4548","LU0114720955.EUR","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972920","title":"Illumina Prices $300 Million Notes Offering Due 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972920","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972920?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:06","pubTimestamp":1786536384,"startTime":"0","endTime":"0","summary":"Illumina prices $300 million notes offering due 2029Illumina priced USD 300 million of 4.95% notes due 2029 under an underwriting agreement led by J.P. Morgan, Citigroup.Closing expected Aug. 17, subj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4K9VGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU2360032135.SGD","BK4535","FTXO","LU0203345920.USD","LU0310800965.SGD","LU0072461881.USD","LU0314106906.USD","BK4585","LU2462157665.USD","BK4504","LU0980610538.SGD","LU1668664300.SGD","LU2236285917.USD","LU0106831901.USD","LU1162221912.USD","LU1201861249.SGD","LU1244550221.USD","LU2125154935.USD","ILMN","IE00BSNM7G36.USD","LU0029874061.USD","GNMX","LU1506573853.SGD","LU0098860793.USD","IYF","BK4588","BK4121","LU1074936037.SGD","BK4548","BK4207","LU0477156953.USD","LU0648001328.SGD","LU2125154778.USD","LU1267930227.SGD","TFNS","LU0170899867.USD","LU1791807156.HKD","LU2417539215.USD","LU0162691827.USD","LU1244550577.SGD","LU0203347892.USD","LU2456880835.USD","GNOM","LU0128526141.USD","LU0320765646.SGD","BK4566","LU0052756011.USD","LU1366192091.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972674","title":"Thermo Fisher Completes Sale of Microbiology Business to Astorg for $1.08 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972674","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972674?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:03","pubTimestamp":1786536209,"startTime":"0","endTime":"0","summary":"Thermo Fisher completes sale of microbiology business to Astorg for $1.08 billionThermo Fisher completed the sale of its microbiology business to private equity firm Astorg for about $1.075 billion.Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL5b7x1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","TMO","BK4534","LU0096362180.USD","LU0708994859.HKD","LU1267930573.SGD","LU1280957306.USD","LU0234572021.USD","LU1064131342.USD","LU2112291526.USD","LU2125910336.SGD","LU0011850046.USD","LU1670628061.USD","LU1815333072.USD","LU2764262908.HKD","FMED","LU0432979614.USD","LU1057294990.SGD","LU2433249047.HKD","LU1988902786.USD","LU1923622291.USD","LU1623119135.USD","LU0266013472.USD","LU0114720955.EUR","GB00BDT5M118.USD","BK4566","LU0128525929.USD","IE0034235188.USD","LU2764263039.SGD","LU1720051017.SGD","BK4581","IE0009355771.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BJJMRZ35.SGD","LU0528227936.USD","LU0316494557.USD","LU2720916845.USD","BK4548","HRTS","LU1791710400.SGD","LU2125909916.SGD","LU2063271972.USD","LU0882574055.USD","LU2468319806.SGD","GNMX","LU1712237335.SGD","LU2125910179.SGD","TMED","LU1854103824.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594972","title":"Thermo Fisher Scientific Completes Sale of Its Microbiology Business to Astorg","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA50LBGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TMO","FMED","LU1720051108.HKD","IE0009355771.USD","LU2125910336.SGD","TMED","LU0011850046.USD","LU1267930573.SGD","LU2125909916.SGD","BK4588","LU2211814178.USD","IE00B19Z8X17.USD","BK4566","LU0061474960.USD","LU1923621640.USD","LU0882574055.USD","LU0432979614.USD","LU0316494557.USD","LU1988902786.USD","LU0096362180.USD","LU2298321311.HKD","BK4534","LU1712237335.SGD","HRTS","IE00B19Z8W00.USD","LU1854104046.USD","LU2764262908.HKD","LU1280957306.USD","IE00BJT1NW94.SGD","BK4533","GNMX","LU0708994859.HKD","LU2092937221.SGD","LU2764263039.SGD","LU0234572021.USD","IE00BQXX3F31.USD","LU0345770308.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU1057294990.SGD","LU2433249047.HKD","LU0208291251.USD","GB00BDT5M118.USD","LU1720051017.SGD","BK4121","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0122379950.USD","LU2357305700.SGD","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974863","title":"Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Brookdale Senior Living (BKD) and Legend Biotech (LEGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974863?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:10","pubTimestamp":1786533037,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Brookdale Senior Livi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-brookdale-senior-living-bkd-and-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-brookdale-senior-living-bkd-and-legend-biotech-legn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","BKD","LEGN","BK4532","BK4185","LU1674673691.USD","SG9999001176.USD","TBXU","HCSG","IE00B19Z3581.USD","LABU","LU0061475181.USD","MEDI","GNMX","VERX","LU0432979614.USD","IDNA","LU1778281490.HKD","XLV","BK4588","LU0029874061.USD","SG9999001176.SGD","LU1430594728.SGD","LU1499592464.USD","IBB","MEMS","LU0234570918.USD","LU2089984988.USD","IE0002270589.USD","LU2417539215.USD","IE00B19Z3B42.SGD","BIB","PBE","IE00B894F039.SGD","LU0417517546.SGD","LU0058720904.USD","VRTX","LU2237438978.USD","LU0757428866.USD","XBI","CANC","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2462157665.USD","LU0079474960.USD","LU1585245621.USD","IBBQ","LU1815336091.USD","BK4505","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658414920","title":"Vertex 1Q Net Y772.00m vs Net Y658.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2658414920","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658414920?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:41","pubTimestamp":1786524060,"startTime":"0","endTime":"0","summary":"Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0432979614.USD","LU1778281490.HKD","LU0566484027.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","TBXU","IBB","LU0823416689.USD","SG9999013999.USD","IE0002141913.USD","LU1430594728.SGD","LU0289739699.SGD","LU0234570918.USD","LU0320765992.SGD","VRTX","LU1674673428.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","BK4588","SGXZ57979304.SGD","LU0058720904.USD","BK4023","LU2089984988.USD","BIB","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0079474960.USD","LU1815336091.USD","PBE","IE00B19Z9P08.USD","VERX","SG9999001176.USD","IE0009355771.USD","IBBQ","LU1093756325.SGD","BK4567","IE00B4R5TH58.HKD","LU2362541513.USD","GNMX","LU1674673691.USD","BK4585","IDNA","LU0889565916.HKD","LU2462157665.USD","LU2237438978.USD","SG9999001176.SGD","BBH","LU0256863811.USD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949165","title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949165","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:23","pubTimestamp":1786487005,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Commercial Officer Chris Freeman disposes of $ 10.75 million in common sharesGuardant Health Chief Commercial Officer Chris Freeman exercised stock options for 63,605 shares on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4khYKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GDOC","LU0109394709.USD","BK4585","EKG","FFOX","PTH","GNMX","GNOM","HELX","BK4551","LU0889565916.HKD","BK4535","LU0320765992.SGD","BK4588","GH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658283943","title":"Illumina Ajukan Form 3; Chief Legal Officer Julie Ann Coletti Laporkan Kepemilikan Manfaat Awal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658283943","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658283943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:28","pubTimestamp":1786480129,"startTime":"0","endTime":"0","summary":"Illumina ajukan Form 3; Chief Legal Officer Julie Ann Coletti laporkan kepemilikan manfaat awalIllumina mengajukan Form 3 untuk Julie Ann Coletti sebagai Chief Legal Officer, dengan tanggal kejadian 0","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL1D0fxf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GNOM","BK4535","LU0128526141.USD","BK4534","GNMX","ILMN","BK4548","BK4588","LU0029874061.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197479","title":"Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197479?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:58","pubTimestamp":1786460297,"startTime":"0","endTime":"0","summary":"Illumina  is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.RBC Capital Markets has an outperform rating and a $230 price target on the stock.Price: 191.86, Change: +0.07, Percent Change: +0.04","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","BK4535","LU0029874061.USD","LU0128525929.USD","LU0128526141.USD","BK4548","BK4207","GSIB","BK4121","BK4585","GNOM","LU0708994859.HKD","LU0029864427.USD","BK4534","LU1267930573.SGD","BK4588","ILMN","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919006","title":"Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919006?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:56","pubTimestamp":1786460205,"startTime":"0","endTime":"0","summary":"Jefferies analyst Akash Tewari maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $633.00. According to TipRanks, Te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-vertex-pharmaceuticals-vrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0256863811.USD","LU0432979614.USD","LU2237438978.USD","IE00B19Z9P08.USD","BK4139","IE00B19Z3B42.SGD","IE00B19Z3581.USD","PBE","SGXZ57979304.SGD","IBB","LU0889565916.HKD","LU0289739699.SGD","LU2236285917.USD","LU0757428866.USD","LU2089984988.USD","BK4023","IE00BFTCPJ56.SGD","TBXU","IE00B894F039.SGD","LU0058720904.USD","IE0002141913.USD","BIB","IBBQ","IE00B2B36J28.USD","LU2417539215.USD","LU2362541513.USD","BBH","LU1778281490.HKD","LU0320765992.SGD","LU1815336091.USD","LU2468319806.SGD","BK4585","IDNA","IE00B19Z9Z06.USD","LU0061475181.USD","LU2362541273.HKD","LU2324357040.USD","SG9999013999.USD","LU2462157665.USD","LU1093756168.USD","VERX","BK4588","BK4533","LU0566484027.USD","LU0234570918.USD","LU1069344957.HKD","SG9999001176.USD","GNMX","VRTX","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658913504","title":"Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658913504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658913504?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:00","pubTimestamp":1786453226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ge-healthcare-technologies-inc-gehc-vertex-pharmaceuticals-vrtx-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-ge-healthcare-technologies-inc-gehc-vertex-pharmaceuticals-vrtx-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","XLV","LU2756315318.SGD","LU0353189680.USD","LU2756315664.SGD","LU0320765992.SGD","LU2417539215.USD","BIB","TBXU","VRTX","UXI","TRUI","MISL","LGHT","LU0820561909.HKD","LU1261432733.SGD","IBB","BBH","LU1084165304.USD","IDNA","AGIO","VERX","XBI","NATO","BK4139","LU0058720904.USD","METV","LU0267386448.USD","SG9999001176.SGD","IE0002270589.USD","LU0157215616.USD","BK4588","ITA","LABU","LU0757428866.USD","GNMX","XAR","LU0417517546.SGD","EXI","LU1093756325.SGD","LU2089984988.USD","IE00B19Z9P08.USD","DFEN","IBBQ","IE0009355771.USD","PBE","PPA","GEHC","GE","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}